​

Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AXSM Stock Forecast

Axsome Therapeutics (AXSM) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $222.43, with a high of $260.00 and a low of $200.00. This represents a 39.45% increase from the last price of $159.50.

$50 $100 $150 $200 $250 $300 High: $260 Avg: $222.43 Low: $200 Last Closed Price: $159.5

AXSM Stock Rating

Axsome Therapeutics stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (96.00%), 1 Hold (4.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 24 Strong Sell Sell Hold Buy Strong Buy

AXSM Price Target Upside V Benchmarks

TypeNameUpside
StockAxsome Therapeutics39.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts92129
Avg Price Target$219.67$219.05$209.34
Last Closing Price$159.50$159.50$159.50
Upside/Downside37.72%37.34%31.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 263161--20
Feb, 263161--20
Jan, 26416---20
Dec, 25416---20
Nov, 25515---20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026RBC Capital$222.00$168.3531.87%39.18%
Feb 24, 2026UBS$251.00$170.8146.95%57.37%
Feb 24, 2026Morgan Stanley$207.00$174.7618.45%29.78%
Feb 24, 2026Guggenheim$220.00$174.7625.89%37.93%
Feb 24, 2026Wells Fargo$202.00$174.7615.59%26.65%
Feb 23, 2026Rudy LiWolfe Research$230.00$174.7631.61%44.20%
Feb 23, 2026Joon LeeTruist Financial$200.00$173.5515.24%25.39%
Feb 23, 2026Jefferies$215.00$173.9023.63%34.80%
Feb 19, 2026Mizuho Securities$230.00$184.7424.50%44.20%
Jan 21, 2026Leonid TimashevRBC Capital$219.00$184.5018.70%37.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026RBC CapitalOutperformOutperformhold
Feb 24, 2026UBSBuyBuyhold
Feb 24, 2026GuggenheimBuyBuyhold
Feb 24, 2026Wells FargoOverweightOverweighthold
Feb 23, 2026Wolfe ResearchOutperforminitialise
Feb 23, 2026Cowen & Co.BuyBuyhold
Jan 29, 2026Cowen & Co.BuyBuyhold
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 16, 2026Piper SandlerOverweightOverweighthold
Jan 14, 2026Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-10 $-4 $2 $8 $14 $20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.60$-5.27$-5.99$-3.68---
Avg Forecast$-4.33$-4.26$-5.46$-1.86$3.49$8.94$14.40
High Forecast$-3.58$-4.09$-4.84$1.33$7.55$15.48$18.28
Low Forecast$-5.22$-4.59$-6.42$-6.84$-1.77$1.68$11.37
Surprise %6.24%23.71%9.71%97.85%---

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.04M$270.60M$385.69M$638.50M---
Avg Forecast$46.98M$268.30M$384.09M$632.39M$1.02B$1.47B$2.00B
High Forecast$54.34M$269.66M$387.81M$761.98M$1.03B$1.47B$2.41B
Low Forecast$40.70M$265.55M$380.46M$529.02M$1.02B$1.47B$1.67B
Surprise %6.51%0.86%0.42%0.97%---

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-187.13M$-239.24M$-287.22M$-183.17M---
Avg Forecast$-196.81M$-197.28M$-255.63M$-117.53M$130.33M$454.59M$654.27M
High Forecast$-162.61M$-186.00M$-219.63M$60.27M$342.78M$703.18M$830.30M
Low Forecast$-236.92M$-208.57M$-291.63M$-310.79M$-80.59M$76.31M$516.45M
Surprise %-4.92%21.27%12.36%55.86%---

AXSM Forecast FAQ

Is Axsome Therapeutics stock a buy?

Axsome Therapeutics stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Axsome Therapeutics is a favorable investment for most analysts.

What is Axsome Therapeutics's price target?

Axsome Therapeutics's price target, set by 25 Wall Street analysts, averages $222.43 over the next 12 months. The price target range spans from $200 at the low end to $260 at the high end, suggesting a potential 39.45% change from the previous closing price of $159.5.

How does Axsome Therapeutics stock forecast compare to its benchmarks?

Axsome Therapeutics's stock forecast shows a 39.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Axsome Therapeutics over the past three months?

  • March 2026: 15.00% Strong Buy, 80.00% Buy, 5.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 15.00% Strong Buy, 80.00% Buy, 5.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Axsome Therapeutics’s EPS forecast?

Axsome Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $3.49, marking a -194.84% decrease from the reported $-3.68 in 2025. Estimates for the following years are $8.94 in 2027, and $14.4 in 2028.

What is Axsome Therapeutics’s revenue forecast?

Axsome Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1.02B, reflecting a 60.05% increase from the reported $638.5M in 2025. The forecast for 2027 is $1.47B, and $2B for 2028.

What is Axsome Therapeutics’s net income forecast?

Axsome Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $130.33M, representing a -171.15% decrease from the reported $-183M in 2025. Projections indicate $454.59M in 2027, and $654.27M in 2028.